PATH-22. Characteristics of various comprehensive genomic profiling tests for central nervous system tumors in Japan since 2023 Article Swipe

PDF

Daisuke Kawauchi , Makoto Ohno , Takaki Omura , Takafumi Koyama ·

YOU? · · 2025 · Open Access · · DOI: https://doi.org/10.1093/neuonc/noaf201.0974

BACKGROUND In Japan, two cancer gene panel (CGP) tests—OncoGuide™ NCC Oncopanel System (NCCG) and FoundationOne® CDx (F1)—were first covered by public insurance in June 2019 and are widely used to identify actionable genetic alterations in brain tumor patients. In August 2023, a new tissue-based CGP test, the GenMineTOP Cancer Genome Profiling System (GMT), also received insurance coverage. GMT broadened the genomic coverage by including 737 cancer-related genes and allowed detection of 455 gene fusions via RNA analysis. This study aimed to evaluate the features and performance of different CGP tests in glioma patients registered from 2023 onward. METHODS Data were obtained from the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) database. Cases of central nervous system (CNS) tumors registered between August 2023 and April 2025 were included. Patients were categorized into three groups based on the CGP used: F1, GMT, or NCCG. We analyzed the types and frequency of genetic alterations identified in each group. RESULTS Among 1,151 eligible cases, 563 underwent F1, 542 GMT, and 46 NCCG. The distribution of CGP usage changed notably over time: in 2023, F1 and GMT accounted for 77.7% and 17.5%, respectively, but by 2025, their shares shifted to 22.4% and 69.3%, indicating a growing preference for GMT. F1 identified the highest number of somatic mutations, with a mean of 11.3 variants per case, compared to 6.5 with GMT and 3.4 with NCCG. Similar patterns were observed for copy number alterations and structural variants, leading to more off-label treatment suggestions in the F1 group. In contrast, GMT demonstrated superior capability in detecting germline mutations, found in 6.1% of CNS cases. CONCLUSIONS CGP tests offer valuable genomic information for guiding therapy, but differences in detection capacity highlight the importance of selecting the appropriate panel based on clinical and diagnostic goals.

Related Topics

Truth And Reconciliation Commission Of Canada

2025 Nba Draft

28 Years Later

Mahmood Mamdani

Reich Ministry Of Public Enlightenment And Propaganda

Concepts

No concepts available.

Metadata

Type: article
Language: en
Landing Page: https://doi.org/10.1093/neuonc/noaf201.0974
PDF: https://academic.oup.com/neuro-oncology/article-pdf/27/Supplement_5/v245/65255739/noaf201.0974.pdf
OA Status: bronze
OpenAlex ID: https://openalex.org/W4416140251

All OpenAlex metadata

Raw OpenAlex JSON

OpenAlex ID: https://openalex.org/W4416140251

Canonical identifier for this work in OpenAlex
DOI: https://doi.org/10.1093/neuonc/noaf201.0974

Digital Object Identifier
Title: PATH-22. Characteristics of various comprehensive genomic profiling tests for central nervous system tumors in Japan since 2023

Work title
Type: article

OpenAlex work type
Language: en

Primary language
Publication year: 2025

Year of publication
Publication date: 2025-11-01

Full publication date if available
Authors: Daisuke Kawauchi, Makoto Ohno, Takaki Omura, Takafumi Koyama

List of authors in order
Landing page: https://doi.org/10.1093/neuonc/noaf201.0974

Publisher landing page
PDF URL: https://academic.oup.com/neuro-oncology/article-pdf/27/Supplement_5/v245/65255739/noaf201.0974.pdf

Direct link to full text PDF
Open access: Yes

Whether a free full text is available
OA status: bronze

Open access status per OpenAlex
OA URL: https://academic.oup.com/neuro-oncology/article-pdf/27/Supplement_5/v245/65255739/noaf201.0974.pdf

Direct OA link when available
Cited by: 0

Total citation count in OpenAlex

Full payload

id	https://openalex.org/W4416140251
doi	https://doi.org/10.1093/neuonc/noaf201.0974
ids.doi	https://doi.org/10.1093/neuonc/noaf201.0974
ids.openalex	https://openalex.org/W4416140251
fwci	0.0
type	article
title	PATH-22. Characteristics of various comprehensive genomic profiling tests for central nervous system tumors in Japan since 2023
biblio.issue	Supplement_5
biblio.volume	27
biblio.last_page	v245
biblio.first_page	v245
is_xpac	False
apc_list.value	4612
apc_list.currency	USD
apc_list.value_usd	4612
apc_paid
language	en
locations[0].id	doi:10.1093/neuonc/noaf201.0974
locations[0].is_oa	True
locations[0].source.id	https://openalex.org/S106908163
locations[0].source.issn	1522-8517, 1523-5866
locations[0].source.type	journal
locations[0].source.is_oa	False
locations[0].source.issn_l	1522-8517
locations[0].source.is_core	True
locations[0].source.is_in_doaj	False
locations[0].source.display_name	Neuro-Oncology
locations[0].source.host_organization	https://openalex.org/P4310311648
locations[0].source.host_organization_name	Oxford University Press
locations[0].source.host_organization_lineage	https://openalex.org/P4310311648
locations[0].license
locations[0].pdf_url	https://academic.oup.com/neuro-oncology/article-pdf/27/Supplement_5/v245/65255739/noaf201.0974.pdf
locations[0].version	publishedVersion
locations[0].raw_type	journal-article
locations[0].license_id
locations[0].is_accepted	True
locations[0].is_published	True
locations[0].raw_source_name	Neuro-Oncology
locations[0].landing_page_url	https://doi.org/10.1093/neuonc/noaf201.0974
indexed_in	crossref
authorships[0].author.id	https://openalex.org/A5068447915
authorships[0].author.orcid	https://orcid.org/0000-0002-1254-9725
authorships[0].author.display_name	Daisuke Kawauchi
authorships[0].countries	JP
authorships[0].affiliations[0].institution_ids	https://openalex.org/I4210156366
authorships[0].affiliations[0].raw_affiliation_string	National Cancer Center Hospital, Tokyo, Japan
authorships[0].institutions[0].id	https://openalex.org/I4210156366
authorships[0].institutions[0].ror	https://ror.org/05asn5035
authorships[0].institutions[0].type	healthcare
authorships[0].institutions[0].lineage	https://openalex.org/I4210137409, https://openalex.org/I4210156366
authorships[0].institutions[0].country_code	JP
authorships[0].institutions[0].display_name	Tokyo National Hospital
authorships[0].author_position	first
authorships[0].raw_author_name	Daisuke Kawauchi
authorships[0].is_corresponding	False
authorships[0].raw_affiliation_strings	National Cancer Center Hospital, Tokyo, Japan
authorships[1].author.id	https://openalex.org/A5055935818
authorships[1].author.orcid	https://orcid.org/0000-0001-8031-4306
authorships[1].author.display_name	Makoto Ohno
authorships[1].countries	JP
authorships[1].affiliations[0].institution_ids	https://openalex.org/I4210156366
authorships[1].affiliations[0].raw_affiliation_string	National Cancer Center Hospital, Tokyo, Japan
authorships[1].institutions[0].id	https://openalex.org/I4210156366
authorships[1].institutions[0].ror	https://ror.org/05asn5035
authorships[1].institutions[0].type	healthcare
authorships[1].institutions[0].lineage	https://openalex.org/I4210137409, https://openalex.org/I4210156366
authorships[1].institutions[0].country_code	JP
authorships[1].institutions[0].display_name	Tokyo National Hospital
authorships[1].author_position	middle
authorships[1].raw_author_name	Makoto Ohno
authorships[1].is_corresponding	False
authorships[1].raw_affiliation_strings	National Cancer Center Hospital, Tokyo, Japan
authorships[2].author.id	https://openalex.org/A5058151515
authorships[2].author.orcid	https://orcid.org/0009-0002-6582-7001
authorships[2].author.display_name	Takaki Omura
authorships[2].countries	JP
authorships[2].affiliations[0].institution_ids	https://openalex.org/I4210156366
authorships[2].affiliations[0].raw_affiliation_string	National Cancer Center Hospital, Tokyo, Japan
authorships[2].institutions[0].id	https://openalex.org/I4210156366
authorships[2].institutions[0].ror	https://ror.org/05asn5035
authorships[2].institutions[0].type	healthcare
authorships[2].institutions[0].lineage	https://openalex.org/I4210137409, https://openalex.org/I4210156366
authorships[2].institutions[0].country_code	JP
authorships[2].institutions[0].display_name	Tokyo National Hospital
authorships[2].author_position	last
authorships[2].raw_author_name	Takaki Omura
authorships[2].is_corresponding	False
authorships[2].raw_affiliation_strings	National Cancer Center Hospital, Tokyo, Japan
authorships[3].author.id	https://openalex.org/A5041593880
authorships[3].author.orcid	https://orcid.org/0000-0001-5807-8458
authorships[3].author.display_name	Takafumi Koyama
authorships[3].countries	JP
authorships[3].affiliations[0].institution_ids	https://openalex.org/I4210156366
authorships[3].affiliations[0].raw_affiliation_string	National Cancer Center Hospital, Tokyo, Japan
authorships[3].institutions[0].id	https://openalex.org/I4210156366
authorships[3].institutions[0].ror	https://ror.org/05asn5035
authorships[3].institutions[0].type	healthcare
authorships[3].institutions[0].lineage	https://openalex.org/I4210137409, https://openalex.org/I4210156366
authorships[3].institutions[0].country_code	JP
authorships[3].institutions[0].display_name	Tokyo National Hospital
authorships[3].author_position	middle
authorships[3].raw_author_name	Takafumi Koyama
authorships[3].is_corresponding	False
authorships[3].raw_affiliation_strings	National Cancer Center Hospital, Tokyo, Japan
has_content.pdf	True
has_content.grobid_xml	False
is_paratext	False
open_access.is_oa	True
open_access.oa_url	https://academic.oup.com/neuro-oncology/article-pdf/27/Supplement_5/v245/65255739/noaf201.0974.pdf
open_access.oa_status	bronze
open_access.any_repository_has_fulltext	False
created_date	2025-11-11T00:00:00
display_name	PATH-22. Characteristics of various comprehensive genomic profiling tests for central nervous system tumors in Japan since 2023
has_fulltext	False
is_retracted	False
updated_date	2025-11-28T06:10:00.302670
primary_topic
cited_by_count	0
locations_count	1
best_oa_location.id	doi:10.1093/neuonc/noaf201.0974
best_oa_location.is_oa	True
best_oa_location.source.id	https://openalex.org/S106908163
best_oa_location.source.issn	1522-8517, 1523-5866
best_oa_location.source.type	journal
best_oa_location.source.is_oa	False
best_oa_location.source.issn_l	1522-8517
best_oa_location.source.is_core	True
best_oa_location.source.is_in_doaj	False
best_oa_location.source.display_name	Neuro-Oncology
best_oa_location.source.host_organization	https://openalex.org/P4310311648
best_oa_location.source.host_organization_name	Oxford University Press
best_oa_location.source.host_organization_lineage	https://openalex.org/P4310311648
best_oa_location.license
best_oa_location.pdf_url	https://academic.oup.com/neuro-oncology/article-pdf/27/Supplement_5/v245/65255739/noaf201.0974.pdf
best_oa_location.version	publishedVersion
best_oa_location.raw_type	journal-article
best_oa_location.license_id
best_oa_location.is_accepted	True
best_oa_location.is_published	True
best_oa_location.raw_source_name	Neuro-Oncology
best_oa_location.landing_page_url	https://doi.org/10.1093/neuonc/noaf201.0974
primary_location.id	doi:10.1093/neuonc/noaf201.0974
primary_location.is_oa	True
primary_location.source.id	https://openalex.org/S106908163
primary_location.source.issn	1522-8517, 1523-5866
primary_location.source.type	journal
primary_location.source.is_oa	False
primary_location.source.issn_l	1522-8517
primary_location.source.is_core	True
primary_location.source.is_in_doaj	False
primary_location.source.display_name	Neuro-Oncology
primary_location.source.host_organization	https://openalex.org/P4310311648
primary_location.source.host_organization_name	Oxford University Press
primary_location.source.host_organization_lineage	https://openalex.org/P4310311648
primary_location.license
primary_location.pdf_url	https://academic.oup.com/neuro-oncology/article-pdf/27/Supplement_5/v245/65255739/noaf201.0974.pdf
primary_location.version	publishedVersion
primary_location.raw_type	journal-article
primary_location.license_id
primary_location.is_accepted	True
primary_location.is_published	True
primary_location.raw_source_name	Neuro-Oncology
primary_location.landing_page_url	https://doi.org/10.1093/neuonc/noaf201.0974
publication_date	2025-11-01
publication_year	2025
referenced_works_count	0
abstract_inverted_index.a	42, 201, 215
abstract_inverted_index.46	168
abstract_inverted_index.F1	181, 206, 250
abstract_inverted_index.In	2, 39, 252
abstract_inverted_index.We	144
abstract_inverted_index.by	20, 63, 191
abstract_inverted_index.in	23, 35, 91, 154, 179, 248, 258, 263, 280
abstract_inverted_index.of	71, 87, 114, 150, 172, 211, 217, 265, 286
abstract_inverted_index.on	136, 292
abstract_inverted_index.or	142
abstract_inverted_index.to	30, 81, 196, 223, 243
abstract_inverted_index.3.4	228
abstract_inverted_index.455	72
abstract_inverted_index.542	165
abstract_inverted_index.563	162
abstract_inverted_index.6.5	224
abstract_inverted_index.737	65
abstract_inverted_index.CDx	16
abstract_inverted_index.CGP	45, 89, 138, 173, 269
abstract_inverted_index.CNS	266
abstract_inverted_index.F1,	140, 164
abstract_inverted_index.GMT	58, 183, 226, 254
abstract_inverted_index.NCC	10
abstract_inverted_index.RNA	76
abstract_inverted_index.The	170
abstract_inverted_index.and	14, 26, 68, 85, 108, 124, 148, 167, 182, 187, 198, 227, 239, 294
abstract_inverted_index.are	27
abstract_inverted_index.but	190, 278
abstract_inverted_index.for	105, 185, 204, 235, 275
abstract_inverted_index.new	43
abstract_inverted_index.per	220
abstract_inverted_index.the	47, 60, 83, 103, 137, 146, 208, 249, 284, 288
abstract_inverted_index.two	4
abstract_inverted_index.via	75
abstract_inverted_index.11.3	218
abstract_inverted_index.2019	25
abstract_inverted_index.2023	96, 123
abstract_inverted_index.2025	126
abstract_inverted_index.6.1%	264
abstract_inverted_index.Data	99
abstract_inverted_index.GMT,	141, 166
abstract_inverted_index.GMT.	205
abstract_inverted_index.June	24
abstract_inverted_index.This	78
abstract_inverted_index.also	54
abstract_inverted_index.copy	236
abstract_inverted_index.each	155
abstract_inverted_index.from	95, 102
abstract_inverted_index.gene	6, 73
abstract_inverted_index.into	132
abstract_inverted_index.mean	216
abstract_inverted_index.more	244
abstract_inverted_index.over	177
abstract_inverted_index.used	29
abstract_inverted_index.were	100, 127, 130, 233
abstract_inverted_index.with	214, 225, 229
abstract_inverted_index.(CGP)	8
abstract_inverted_index.(CNS)	118
abstract_inverted_index.1,151	159
abstract_inverted_index.2023,	41, 180
abstract_inverted_index.2025,	192
abstract_inverted_index.22.4%	197
abstract_inverted_index.77.7%	186
abstract_inverted_index.Among	158
abstract_inverted_index.April	125
abstract_inverted_index.Cases	113
abstract_inverted_index.NCCG.	143, 169, 230
abstract_inverted_index.aimed	80
abstract_inverted_index.based	135, 291
abstract_inverted_index.brain	36
abstract_inverted_index.case,	221
abstract_inverted_index.first	18
abstract_inverted_index.found	262
abstract_inverted_index.genes	67
abstract_inverted_index.offer	271
abstract_inverted_index.panel	7, 290
abstract_inverted_index.study	79
abstract_inverted_index.test,	46
abstract_inverted_index.tests	90, 270
abstract_inverted_index.their	193
abstract_inverted_index.three	133
abstract_inverted_index.time:	178
abstract_inverted_index.tumor	37
abstract_inverted_index.types	147
abstract_inverted_index.usage	174
abstract_inverted_index.used:	139
abstract_inverted_index.(GMT),	53
abstract_inverted_index.(NCCG)	13
abstract_inverted_index.17.5%,	188
abstract_inverted_index.69.3%,	199
abstract_inverted_index.August	40, 122
abstract_inverted_index.Cancer	49, 106
abstract_inverted_index.Center	104
abstract_inverted_index.Genome	50
abstract_inverted_index.Japan,	3
abstract_inverted_index.System	12, 52
abstract_inverted_index.cancer	5
abstract_inverted_index.cases,	161
abstract_inverted_index.cases.	267
abstract_inverted_index.glioma	92
abstract_inverted_index.goals.	296
abstract_inverted_index.group.	156, 251
abstract_inverted_index.groups	134
abstract_inverted_index.number	210, 237
abstract_inverted_index.public	21
abstract_inverted_index.shares	194
abstract_inverted_index.system	117
abstract_inverted_index.tumors	119
abstract_inverted_index.widely	28
abstract_inverted_index.(C-CAT)	111
abstract_inverted_index.METHODS	98
abstract_inverted_index.RESULTS	157
abstract_inverted_index.Similar	231
abstract_inverted_index.allowed	69
abstract_inverted_index.between	121
abstract_inverted_index.central	115
abstract_inverted_index.changed	175
abstract_inverted_index.covered	19
abstract_inverted_index.fusions	74
abstract_inverted_index.genetic	33, 151
abstract_inverted_index.genomic	61, 273
abstract_inverted_index.growing	202
abstract_inverted_index.guiding	276
abstract_inverted_index.highest	209
abstract_inverted_index.leading	242
abstract_inverted_index.nervous	116
abstract_inverted_index.notably	176
abstract_inverted_index.onward.	97
abstract_inverted_index.shifted	195
abstract_inverted_index.somatic	212
abstract_inverted_index.Abstract	0
abstract_inverted_index.Advanced	109
abstract_inverted_index.Genomics	107
abstract_inverted_index.Patients	129
abstract_inverted_index.analyzed	145
abstract_inverted_index.capacity	282
abstract_inverted_index.clinical	293
abstract_inverted_index.compared	222
abstract_inverted_index.coverage	62
abstract_inverted_index.eligible	160
abstract_inverted_index.evaluate	82
abstract_inverted_index.features	84
abstract_inverted_index.germline	260
abstract_inverted_index.identify	31
abstract_inverted_index.observed	234
abstract_inverted_index.obtained	101
abstract_inverted_index.patients	93
abstract_inverted_index.patterns	232
abstract_inverted_index.received	55
abstract_inverted_index.superior	256
abstract_inverted_index.therapy,	277
abstract_inverted_index.valuable	272
abstract_inverted_index.variants	219
abstract_inverted_index.Oncopanel	11
abstract_inverted_index.Profiling	51
abstract_inverted_index.accounted	184
abstract_inverted_index.analysis.	77
abstract_inverted_index.broadened	59
abstract_inverted_index.contrast,	253
abstract_inverted_index.coverage.	57
abstract_inverted_index.database.	112
abstract_inverted_index.detecting	259
abstract_inverted_index.detection	70, 281
abstract_inverted_index.different	88
abstract_inverted_index.frequency	149
abstract_inverted_index.highlight	283
abstract_inverted_index.included.	128
abstract_inverted_index.including	64
abstract_inverted_index.insurance	22, 56
abstract_inverted_index.off-label	245
abstract_inverted_index.patients.	38
abstract_inverted_index.selecting	287
abstract_inverted_index.treatment	246
abstract_inverted_index.underwent	163
abstract_inverted_index.variants,	241
abstract_inverted_index.BACKGROUND	1
abstract_inverted_index.GenMineTOP	48
abstract_inverted_index.actionable	32
abstract_inverted_index.capability	257
abstract_inverted_index.diagnostic	295
abstract_inverted_index.identified	153, 207
abstract_inverted_index.importance	285
abstract_inverted_index.indicating	200
abstract_inverted_index.mutations,	213, 261
abstract_inverted_index.preference	203
abstract_inverted_index.registered	94, 120
abstract_inverted_index.structural	240
abstract_inverted_index.(F1)—were	17
abstract_inverted_index.CONCLUSIONS	268
abstract_inverted_index.alterations	34, 152, 238
abstract_inverted_index.appropriate	289
abstract_inverted_index.categorized	131
abstract_inverted_index.differences	279
abstract_inverted_index.information	274
abstract_inverted_index.performance	86
abstract_inverted_index.suggestions	247
abstract_inverted_index.Therapeutics	110
abstract_inverted_index.demonstrated	255
abstract_inverted_index.distribution	171
abstract_inverted_index.tissue-based	44
abstract_inverted_index.respectively,	189
abstract_inverted_index.cancer-related	66
abstract_inverted_index.FoundationOne®	15
abstract_inverted_index.tests—OncoGuide™	9
cited_by_percentile_year
countries_distinct_count	1
institutions_distinct_count	4
citation_normalized_percentile